# FDA WARNING_LETTER - Customceutical Compounding - March 08, 2019

Source: https://www.keypedia.com/records/warning_letter/customceutical-compounding/ab4c85af-d402-4143-8a96-294d831bfff5

> FDA WARNING_LETTER for Customceutical Compounding on March 08, 2019. Product: Drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: WARNING_LETTER
- Company Name: Customceutical Compounding
- Inspection Date: 2019-03-08
- Product Type: Drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: On August 25, 2020, the FDA issued a Warning Letter to Customceutical Compounding, LLC, following an inspection from February 27 to March 8, 2019. The inspection revealed serious deficiencies in sterile drug product production, leading to adulterated drug products under FDCA Section 501(a)(2)(A) due to insanitary conditions.

Key violations included:
- Poor aseptic processing practices, such as failure to sanitize materials and personnel exposing facial skin in ISO 5 areas.
- Inadequate product evaluation and remedial action after microbial contamination on a technician's glove.
- Failure to perform adequate smoke studies under dynamic conditions for unidirectional airflow in ISO 5 areas.
- Use of non-sterile cleaning wipes in the ISO 5 area.
- Inadequate sanitization of equipment and insufficient disinfectant contact time.
- Improper gowning procedures, allowing apparel to touch the floor.
- Inadequate containment and cleaning for hazardous drug products, leading to potential cross-contamination.

The firm ceased sterile compounding on March 29, 2019, and initiated a voluntary recall of sterile injectables and solutions on April 8, 2019. The FDA found the firm's corrective action response regarding cross-contamination inadequate due to insufficient documentation (e.g., lack of detailed SOPs, training records, and audit documentation).

The FDA strongly recommends a comprehensive

## Related Officers

- [Director of Investigations Branch](https://www.keypedia.com/people/katherine-e-jacobitz/9a713b44-95c4-43a2-83bb-8d30062d8345)

Company: https://www.keypedia.com/companies/customceutical-compounding/6c2f3ad8-fba5-417e-a9e6-ae9bb20991a6

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6